Exclusive Summary

• Ursodeoxycholic Acid (UDCA) is an off-patent drug, offering low entry barriers for generic manufacturers globally.
• It addresses numerous liver and gallbladder diseases, with a large and growing global patient population, ensuring sustained market demand.
• Positioned as a WHO essential medicine and widely recommended as first-line or standard therapy by international guidelines, solidifying its clinical acceptance.
• Exhibits significant cost advantages over originator drugs, making it an attractive, affordable option that enhances patient access and reduces healthcare expenditure globally.
• Chinese suppliers capable of providing internationally certified quality and comprehensive registration dossiers possess a strong competitive edge for rapid global market entry.